• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.允许HIV-1感染的CCR5变体对CCL3、CCL4和CCL5表现出不同的功能反应。
Genes Immun. 2005 Oct;6(7):609-19. doi: 10.1038/sj.gene.6364247.
2
Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function.天然存在的CCR5细胞外和跨膜结构域变体影响HIV-1共受体和配体结合功能。
J Biol Chem. 1999 Jun 4;274(23):16228-34. doi: 10.1074/jbc.274.23.16228.
3
Aminooxypentane addition to the chemokine macrophage inflammatory protein-1alpha P increases receptor affinities and HIV inhibition.向趋化因子巨噬细胞炎性蛋白-1α P 添加氨基氧基戊烷可增加受体亲和力并抑制HIV。
J Biol Chem. 2000 Dec 15;275(50):39254-61. doi: 10.1074/jbc.M006768200.
4
Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.CCR5嗜性1型人类免疫缺陷病毒包膜的V2和V3区域参与对巨噬细胞炎性蛋白1α敏感性降低的过程。
J Virol. 2000 Feb;74(4):1787-93. doi: 10.1128/jvi.74.4.1787-1793.2000.
5
Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.生理和病毒趋化因子以及HIV-1包膜糖蛋白与CCR5结合的分子解剖学:RANTES、MIP-1α和vMIP-II结合的一级结构要求差异
J Mol Biol. 2001 Nov 9;313(5):1181-93. doi: 10.1006/jmbi.2001.5086.
6
LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.LD78β是人类MIP-1α(LD78α)的非等位基因变体,具有增强的受体相互作用和强大的HIV抑制活性。
J Biol Chem. 1999 Jun 18;274(25):17478-83. doi: 10.1074/jbc.274.25.17478.
7
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.HIV-1辅助受体使用情况的体内演变以及对趋化因子介导抑制作用的敏感性。
Nat Med. 1997 Nov;3(11):1259-65. doi: 10.1038/nm1197-1259.
8
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.趋化因子的核心结构域与CCR5细胞外结构域结合,而它们的氨基末端与跨膜螺旋束相互作用。
J Biol Chem. 2003 Feb 14;278(7):5179-87. doi: 10.1074/jbc.M205684200. Epub 2002 Dec 3.
9
A chimeric MIP-1alpha/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors.一种嵌合的MIP-1α/趋化因子RANTES蛋白展示了利用趋化因子RANTES蛋白的不同区域来结合并激活其受体。
J Leukoc Biol. 2001 Jun;69(6):977-85.
10
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.趋化因子受体CCR5与其配体的相互作用:HIV-1 gp120结合的多个结构域和趋化因子结合的单个结构域。
J Exp Med. 1997 Oct 20;186(8):1373-81. doi: 10.1084/jem.186.8.1373.

引用本文的文献

1
Pro-inflammatory macrophages suppress HIV replication in humanized mice and co-cultures.促炎巨噬细胞抑制人源化小鼠和共培养物中的 HIV 复制。
Front Immunol. 2024 Nov 7;15:1439328. doi: 10.3389/fimmu.2024.1439328. eCollection 2024.
2
Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning.基于免疫的 COVID-19 严重程度和慢性程度预测,使用机器学习解码。
Front Immunol. 2021 Jun 28;12:700782. doi: 10.3389/fimmu.2021.700782. eCollection 2021.
3
CCL4 enhances preosteoclast migration and its receptor CCR5 downregulation by RANKL promotes osteoclastogenesis.四氯化碳通过增强核因子-κB 受体活化因子配体(RANKL)诱导的破骨前体细胞迁移及其受体 CCR5 的下调促进破骨细胞的生成。
Cell Death Dis. 2018 May 1;9(5):495. doi: 10.1038/s41419-018-0562-5.
4
Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning.通过深度突变扫描绘制人类趋化因子受体的相互作用位点。
J Immunol. 2018 Jun 1;200(11):3825-3839. doi: 10.4049/jimmunol.1800343. Epub 2018 Apr 20.
5
mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.新型转录激活样效应因子核酸酶(TALEN)的mRNA转染有助于高效敲除HIV共受体CCR5。
Nucleic Acids Res. 2015 Jun 23;43(11):5560-71. doi: 10.1093/nar/gkv469. Epub 2015 May 11.

本文引用的文献

1
CCL3L1 dose and HIV-1 susceptibility.CCL3L1剂量与HIV-1易感性
Trends Mol Med. 2005 May;11(5):203-6. doi: 10.1016/j.molmed.2005.03.003.
2
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.含CCL3L1基因的片段重复对HIV-1/艾滋病易感性的影响。
Science. 2005 Mar 4;307(5714):1434-40. doi: 10.1126/science.1101160. Epub 2005 Jan 6.
3
Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent.激动剂诱导的C-C趋化因子受体5的内吞作用依赖于网格蛋白。
Mol Biol Cell. 2005 Feb;16(2):902-17. doi: 10.1091/mbc.e04-08-0687. Epub 2004 Dec 9.
4
A novel CCR5 mutation selectively affects immunoreactivity and fusogenic property of the HIV co-receptor.
AIDS. 2004 Aug 20;18(12):1729-32. doi: 10.1097/01.aids.0000131382.15232.dc.
5
Functional redundancy of the human CCL4 and CCL4L1 chemokine genes.
Biochem Biophys Res Commun. 2004 Jul 30;320(3):927-31. doi: 10.1016/j.bbrc.2004.06.039.
6
CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis.CCR5-Δ32突变与原发性硬化性胆管炎密切相关。
Genes Immun. 2004 Sep;5(6):444-50. doi: 10.1038/sj.gene.6364113.
7
pH-independent endocytic cycling of the chemokine receptor CCR5.趋化因子受体CCR5的pH非依赖性内吞循环
Traffic. 2004 Jul;5(7):529-43. doi: 10.1111/j.1600-0854.2004.00200.x.
8
CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response?丙型肝炎中的C-C趋化因子受体5(CCR5)——处于抗病毒免疫反应的十字路口?
J Antimicrob Chemother. 2004 Jun;53(6):895-8. doi: 10.1093/jac/dkh239. Epub 2004 May 5.
9
Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4.HIV-1以及天然配体与趋化因子受体CCR5和CXCR4相互作用的表位的分子图谱。
AIDS. 2003 Dec 5;17(18):2571-9. doi: 10.1097/00002030-200312050-00004.
10
Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.小分子CCR5拮抗剂SCH-351125和SCH-350581抑制1型人类免疫缺陷病毒进入的机制分析。
J Virol. 2003 May;77(9):5201-8. doi: 10.1128/jvi.77.9.5201-5208.2003.

允许HIV-1感染的CCR5变体对CCL3、CCL4和CCL5表现出不同的功能反应。

Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.

作者信息

Dong H-F, Wigmore K, Carrington M N, Dean M, Turpin J A, Howard O M Z

机构信息

Basic Research Program, SAIC Frederick, MD 21702, USA.

出版信息

Genes Immun. 2005 Oct;6(7):609-19. doi: 10.1038/sj.gene.6364247.

DOI:10.1038/sj.gene.6364247
PMID:16015368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1369982/
Abstract

CCR5 is one of the primary coreceptors for Env-mediated fusion between cells and human immunodeficiency virus type 1 (HIV-1). Analyses of CCR5 variants in cohorts of HIV-1 high-risk individuals led to the identification of multiple single amino-acid substitutions, which may have functional consequences. This study focused on eight naturally occurring allelic variants located between amino-acid residues 60 and 334 of CCR5. All studied allelic variants were highly expressed on the cell surface of HEK-293 cells and permissive for HIV-1 infection. Variant G301V showed 3.5-fold increase in 50% effective concentration (EC(50)) for CCL4 (MIP 1beta) in a competitive binding assay. There was also a significant reduction in CCL5 (RANTES) EC(50) for the R223Q, A335V and Y339F variants. The most unexpected functional abnormality was exhibited by the R60S variant that exhibited a loss of ligand-induced desensitization in chemotaxis assays, but showed normal CCL4 and CCL5 binding avidity. This mutation is located in the first intracellular loop, a domain that has not previously been shown to be involved in receptor desensitization. In conclusion, our results support earlier studies showing that these naturally occurring point mutations do not limit HIV-1 infection, and indicated that single amino-acid changes can have unexpected functional consequences.

摘要

CCR5是Env介导的细胞与1型人类免疫缺陷病毒(HIV-1)之间融合的主要共受体之一。对HIV-1高危个体队列中的CCR5变体进行分析后,鉴定出多个单氨基酸取代,这些取代可能具有功能影响。本研究聚焦于位于CCR5氨基酸残基60至334之间的8个天然存在的等位基因变体。所有研究的等位基因变体均在HEK-293细胞表面高度表达,并允许HIV-1感染。在竞争性结合试验中,变体G301V对CCL4(MIP 1β)的50%有效浓度(EC50)增加了3.5倍。R223Q、A335V和Y339F变体的CCL5(RANTES)EC50也显著降低。最出乎意料的功能异常由R60S变体表现出来,该变体在趋化试验中表现出配体诱导的脱敏丧失,但CCL4和CCL5结合亲和力正常。此突变位于第一个细胞内环,该结构域以前未被证明参与受体脱敏。总之,我们的结果支持早期研究,表明这些天然存在的点突变不会限制HIV-1感染,并表明单氨基酸变化可能产生意想不到的功能后果。